Compare SVC & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVC | LAB |
|---|---|---|
| Founded | 1995 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.4M | 449.9M |
| IPO Year | N/A | 2011 |
| Metric | SVC | LAB |
|---|---|---|
| Price | $1.89 | $1.49 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $2.75 | $1.35 |
| AVG Volume (30 Days) | 1.3M | ★ 2.0M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,873,944,000.00 | $169,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 79.77 |
| 52 Week Low | $1.55 | $0.92 |
| 52 Week High | $3.08 | $2.25 |
| Indicator | SVC | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 52.01 | 63.99 |
| Support Level | $1.76 | $1.42 |
| Resistance Level | $1.88 | $1.51 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 96.97 | 70.00 |
Service Properties Trust is a real estate investment trust that owns hotel properties. These properties are located in the United States, along with Canada and Puerto Rico. The company operates through its hotel investment unit and net lease investments. The firm derives the majority of its revenue from the hotel real estate investments unit. The hotels are distinguished between their service levels, which include full service, select service, and extended stay; and chain scale, which includes luxury, upper upscale, upscale, upper midscale, and midscale. The hotels are extended stay or upscale. Some of the hotel brands include Courtyard by Marriott, Royal Sonesta, Crowne Plaza Hotels & Resorts, and Hyatt Place.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.